Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers

Chemico-Biological Interactions

Volumn 202, Issue 1-3, 2013, Pages 234-242

  Matsunaga, Toshiyuki ^a   Hojo, Aki ^a   Yamane, Yumi ^a   Endo, Satoshi ^a   El Kabbani, Ossama ^b   Hara, Akira ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Aldo keto reductase; Cisplatin; Colon cancer cells; Drug resistance; Proteasome

Indexed keywords

20ALPHA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; 4 HYDROXYNONENAL; 4 OXO 2 NONENAL; ALANINE; ALDEHYDE; ALDEHYDE REDUCTASE; ALDO KETO REDUCTASE 1A1; ALDO KETO REDUCTASE 1B1; ALDO KETO REDUCTASE 1B10; ALDO KETO REDUCTASE 1C2; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CISPLATIN; LEUCINE; OXIDOREDUCTASE INHIBITOR; PROTEASOME; UNCLASSIFIED DRUG;

CANCER CELL; CELL DAMAGE; COLON CANCER; CONFERENCE PAPER; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

20-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; ALDEHYDES; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HT29 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MCF-7 CELLS; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84875211359     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2012.09.024     Document Type: Conference Paper

References (65)

1. H. Baruah, C.G. Barry, and U. Bierbach Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation Curr. Top. Med. Chem. 4 2004 1537 1549
2. Y.I. Chirino, and J. Pedraza-Chaverri Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity Exp. Toxicol. Pathol. 61 2009 223 242
3. G. Wang, E. Reed, and Q.Q. Li Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer Oncol. Rep. 12 2004 955 965
4. P.J. Loehrer, and L.H. Einhorn Drugs five years later. Cisplatin Ann. Intern. Med. 100 1984 704 713
5. H. Bleiberg Oxaliplatin (L-OHP): a new reality in colorectal cancer Br. J. Cancer 77 1998 1 3
6. M.J. McKeage New-generation platinum drugs in the treatment of cisplatin-resistant cancers Expert Opin. Investig. Drugs 14 2005 1033 1046
7. L. Ekblad, J. Kjellström, and A. Johnsson Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells Anticancer Drugs 21 2010 523 531
8. B.K. Stordal, M.W. Davey, and R.A. Davey Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells Cancer Chemother. Pharmacol. 58 2006 256 265
9. T. Matsunaga, Y. Wada, S. Endo, M. Soda, O. El-Kabbani, and A. Hara Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers Front. Pharmacol. 3 2012 5
10. K. Nooter, and G. Stoter Molecular mechanisms of multidrug resistance in cancer chemotherapy Pathol. Res. Pract. 192 1996 768 780
11. L. Wei, T. Xue, J. Wang, B. Chen, Y. Lei, Y. Huang, H. Wang, and X. Xin Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer Int. J. Cancer 125 2009 791 806
12. J.E. Biaglow, and R.A. Miller The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy Cancer Biol. Ther. 4 2005 6 13
13. J.M. Cho, S. Manandhar, H.R. Lee, H.M. Park, and M.K. Kwak Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance Cancer Lett. 260 2008 96 108
14. S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, K. Itoh, and M. Yamamoto Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer Clin. Cancer Res. 15 2009 3423 3432
15. O.A. Barski, S.M. Tipparaju, and A. Bhatnagar The aldo-keto reductase superfamily and its role in drug metabolism and detoxification Drug Metab. Rev. 40 2008 553 624
16. M.E. Burczynski, G.R. Sridhar, N.T. Palackal, and T.M. Penning The reactive oxygen species- and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the α,β-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene J. Biol. Chem. 276 2001 2890 2897
17. J.J. Hung, K.C. Chow, H.W. Wang, and L.S. Wang Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung Anticancer Res. 26 2006 2949 2955
18. M.C. Byrns, L. Duan, S.H. Lee, I.A. Blair, and T.M. Penning Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer J. Steroid Biochem. Mol. Biol. 118 2010 177 187
19. T. Smuc, and T.L. Rizner Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer Mol. Cell. Endocrinol. 301 2009 74 82
20. Y.J. Chen, C.C. Yuan, K.C. Chow, P.H. Wang, C.R. Lai, M.S. Yen, and L.S. Wang Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients Gynecol. Oncol. 97 2005 110 117
21. H.B. Deng, M. Adikari, H.K. Parekh, and H. Simpkins Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase Cancer Chemother. Pharmacol. 54 2004 301 307
22. J. Chen, M. Adikari, R. Pallai, H.K. Parekh, and H. Simpkins Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells Cancer Chemother. Pharmacol. 61 2008 979 987
23. H.B. Deng, H.K. Parekh, K.C. Chow, and H. Simpkins Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells J. Biol. Chem. 277 2002 15035 15043
24. H.W. Wang, C.P. Lin, J.H. Chiu, K.C. Chow, K.T. Kuo, C.S. Lin, and L.S. Wang Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin Int. J. Cancer 120 2007 2019 2027
25. M. Ueda, Y.C. Hung, J.T. Chen, S.H. Chiou, H.H. Huang, T.Y. Lin, Y. Terai, and K.C. Chow Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer Gynecol. Oncol. 102 2006 173 181
26. S.H. Lee, and I.A. Blair Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation Chem. Res. Toxicol. 13 2000 698 702
27. H. Esterbauer, and W. Weger Uber die Wirkungen von aldehyden auf gesunde und maligne zellen. 3. Mitt: Synthese von homologen 4-hydroxy-2-alkenalen Monatsh. Chem. 98 1967 1994 2000
28. O. El-Kabbani, P.J. Scammells, J. Gosling, U. Dhagat, S. Endo, T. Matsunaga, M. Soda, and A. Hara Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20α-hydroxysteroid dehydrogenase (AKR1C1) J. Med. Chem. 52 2009 3259 3264
29. S. Usui, T. Matsunaga, S. Ukai, and T. Kiho Growth suppressing activity for endothelial cells induced from macrophages by carboxymethylated curdlan Biosci. Biotechnol. Biochem. 61 1997 1924 1925
30. S. Endo, T. Matsunaga, C. Ohta, M. Soda, A. Kanamori, Y. Kitade, S. Ohno, K. Tajima, O. El-Kabbani, and A. Hara Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol Chem. Biol. Interact. 191 2011 261 268
31. T. Iino, M. Tabata, S. Takikawa, H. Sawada, H. Shintaku, S. Ishikura, and A. Hara Tetrahydrobiopterin is synthesized from 6-pyruvoyl-tetrahydropterin by the human aldo-keto reductase AKR1 family members Arch. Biochem. Biophys. 416 2003 180 187
32. S. Endo, T. Matsunaga, H. Mamiya, C. Ohta, M. Soda, Y. Kitade, K. Tajima, H.T. Zhao, O. El-Kabbani, and A. Hara Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids Arch. Biochem. Biophys. 487 2009 1 9
33. H. Shiraishi, K. Matsuura, T. Kume, and A. Hara Expression of mRNAs for dihydrodiol dehydrogenase isoforms in human tissues Adv. Exp. Med. Biol. 463 1999 539 544
34. Y.M. Yang, S. Lee, C.W. Nam, J.H. Ha, M. Jayaraman, D.N. Dhanasekaran, C.H. Lee, M.K. Kwak, and S.G. Kim G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation Carcinogenesis 31 2010 1230 1237
35. A. Johnsen, J. France, M.S. Sy, and C.V. Harding Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines Cancer Res. 58 1998 3660 3667
36. K. Kim, J.M. Brush, P.A. Watson, N.A. Cacalano, K.S. Iwamoto, and W.H. McBride Epidermal growth factor receptor VIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation Mol. Cancer Res. 6 2008 426 434
37. Y. Deyashiki, A. Ogasawara, T. Nakayama, M. Nakanishi, Y. Miyabe, K. Sato, and A. Hara Molecular cloning of two human liver 3α-hydroxysteroid/ dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder Biochem. J. 299 1994 545 552
38. T. Matsunaga, M. Haga, G. Watanabe, Y. Shinoda, S. Endo, Y. Kajiwara, H. Tanaka, N. Inagaki, O. El-Kabbani, and A. Hara 9,10-Phenanthrenequinone promotes secretion of pulmonary aldo-keto reductases with surfactant Cell Tissue Res. 347 2012 407 417
39. K. Matsuura, A. Hara, Y. Deyashiki, H. Iwasa, T. Kume, S. Ishikura, H. Shiraishi, and Y. Katagiri Roles of the C-terminal domains of human dihydrodiol dehydrogenase isoforms in the binding of substrates and modulators: probing with chimaeric enzymes Biochem. J. 336 1998 429 436
40. 2 11-ketoreductase activity J. Biochem. 124 1998 940 946
41. T. Matsunaga, M. Arakaki, T. Kamiya, M. Haga, S. Endo, O. El-Kabbani, and A. Hara Nitric oxide mitigates apoptosis in human endothelial cells induced by 9,10-phenanthrenequinone: role of proteasomal function Toxicology 268 2010 191 197
42. T. Matsunaga, S. Kotamraju, S.V. Kalivendi, A. Dhanasekaran, J. Joseph, and B. Kalyanaraman Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide J. Biol. Chem. 279 2004 28614 28624
43. M.L. Heaney, J.R. Gardner, N. Karasavvas, D.W. Golde, D.A. Scheinberg, E.A. Smith, and O.A. O'Connor Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs Cancer Res. 68 2008 8031 8038
44. S. Osbild, L. Brault, E. Battaglia, and D. Bagrel Resistance to cisplatin and adriamycin is associated with the inhibition of glutathione efflux in MCF-7-derived cells Anticancer Res. 26 2006 3595 3600
45. P. Bragado, A. Armesilla, A. Silva, and A. Porras Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation Apoptosis 12 2007 1733 1742
46. C.T. Aiken, R.M. Kaake, X. Wang, and L. Huang Oxidative stress-mediated regulation of proteasome complexes Mol. Cell. Proteomics 10 2011 R110.006924
47. J. Adams The proteasome: structure, function, and role in the cell Cancer Treat. Rev. 29 2003 3 9
48. Q.Q. Li, M.K. Yunmbam, X. Zhong, J.J. Yu, E.G. Mimnaugh, L. Neckers, and E. Reed Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression Cell Mol. Biol. (Noisy-le-grand) 47 2001 61 72
49. A.M. Fribley, B. Evenchik, Q. Zeng, B.K. Park, J.Y. Guan, H. Zhang, T.J. Hale, M.S. Soengas, R.J. Kaufman, and C.Y. Wang Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa J. Biol. Chem. 281 2006 31440 31447
50. I. Młynarczuk-Biały, H. Roeckmann, U. Kuckelkorn, B. Schmidt, S. Umbreen, J. Gołab, A. Ludwig, C. Montag, L. Wiebusch, C. Hagemeier, D. Schadendorf, P.M. Kloetzel, and U. Seifert Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells Cancer Res. 66 2006 7598 7605
51. K. Tanaka Role of proteasomes modified by interferon-gamma in antigen processing J. Leukoc. Biol. 56 1994 571 575
52. A.M. Pickering, R.A. Linder, H. Zhang, H.J. Forman, and K.J. Davies Nrf2-dependent induction of proteasome and Pa28αβ regulator are required for adaptation to oxidative stress J. Biol. Chem. 287 2012 10021 10031
53. + and ursodeoxycholate Biochemistry 40 2001 10161 10168
54. A.K. MacLeod, M. McMahon, S.M. Plummer, L.G. Higgins, T.M. Penning, K. Igarashi, and J.D. Hayes Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds Carcinogenesis 30 2009 1571 1580
55. C.D. Klaassen, and S.A. Reisman Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver Toxicol. Appl. Pharmacol. 244 2010 57 65
56. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, T. Shibata, M. Yamamoto, and S. Hirohashi Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res. 68 2008 1303 1309
57. J.D. Hayes, and M. McMahon NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer Trends Biochem. Sci. 34 2009 176 188
58. N.J. Yoo, H.R. Kim, Y.R. Kim, C.H. An, and S.H. Lee Somatic mutations of the KEAP1 gene in common solid cancers Histopathology 60 2012 943 952
59. D.P. Brown, H. Chin-Sinex, B. Nie, M.S. Mendonca, and M. Wang Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer Cancer Chemother. Pharmacol. 63 2009 723 730
60. C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli, and M.P. Rigobello Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells Free Radic. Biol. Med. 42 2007 872 881
61. C.M. Rudin, Z. Yang, L.M. Schumaker, D.J. VanderWeele, K. Newkirk, M.J. Egorin, E.G. Zuhowski, and K.J. Cullen Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance Cancer Res. 63 2003 312 318
62. F.X. Ruiz, S. Porté, O. Gallego, A. Moro, A. Ardèvol, A. Del Río-Espínola, C. Rovira, J. Farrés, and X. Parés Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily Biochem. J. 440 2011 335 344
63. T. Grune, and K.J. Davies The proteasomal system and HNE-modified proteins Mol. Aspects Med. 24 2003 195 204
64. B. Ebert, M. Kisiela, V. Wsól, and E. Maser Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29 Chem. Biol. Interact. 191 2011 239 249
65. M. Wehenkel, J-.O. Ban, Y-.K. Ho, K.C. Carmony, J.T. Hong, and K.B. Kim A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice Br. J. Cancer 107 2012 53 62